摘要
目的探讨转录因子Elf-1在非小细胞肺癌中表达的意义。方法收集72例非小细胞肺癌组织,应用组织芯片仪制备组织芯片,采用免疫组化PowerVisionTM-9000(PV-9000)法对其进行Elf-1标记,并分析Elf-1的表达与临床病理因素之间的关系。结果Elf-1阳性染色定位于肺癌细胞胞核及胞质。在72例非小细胞肺癌组织中,Elf-1阳性表达53例(73.61%),其表达强度与非小细胞肺癌的分化程度有关(χ2=8.274,P<0.05);不同临床分期的非小细胞肺癌组织中Elf-1表达强度差异有显著性(2χ=-4.556^-2.501,P<0.01);Elf-1表达强度在淋巴结有转移组显著高于淋巴结无转移组(Z=-3.316,P<0.01);Elf-1的表达强度与病人的年龄、性别、原发瘤大小及组织病理学类型均无关(P>0.05)。结论Elf-1在非小细胞肺癌的发生过程中有一定的作用,可能成为判定非小细胞肺癌恶性程度、评估其侵袭性及转移性的重要指标。
Objective To study the expression of Elf-1 in non-small cell lung cancer （NSCLC） and its clinical significance. Methods Tissue microarray from 72 cases of NSCLC was constructed. The expression of Elf-1 was detected by immunohistochemistry staining with PV-9000 method. Results Elf-1 was mostly expressed in nucleus and in cytoplasm. Positive Elf-1 was observed in 53 cases （73.61%）, its intensity of expression was related to the differentiation of the cancer （χ2 =8. 274, P〈0. 05）, and significant differences were noted between different clinical stages （χ2 =-4. 556-2. 501 ,P〈0.01）. The intensity of Elf-1 expression was significantly higher in the group with lymph node metastasis than that without （Z= --3. 316 ,P〈0.01）, but it was not related to age, gender, tumor size and histological type （P〉0.05）. Conclusion Elf-1 may play a role in NSCLC, and may serve as an important parameter for evaluating its malignancy, invasion and metastasis.
出处
《青岛大学医学院学报》
CAS
2008年第1期59-60,63,共3页
Acta Academiae Medicinae Qingdao Universitatis
